LXEO
MaterialsLexeo Therapeutics Inc
$6.23+0.27 (+4.53%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving LXEO Today?
No stock-specific AI insight has been generated for LXEO yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$489M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume617K
Avg Volume (10D)—
Shares Outstanding78.5M
LXEO News
20 articles- Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual MeetingYahoo Finance·Apr 27, 2026
- Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely?Yahoo Finance·Apr 1, 2026
- Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsYahoo Finance·Mar 30, 2026
- Lexeo Therapeutics to Participate in the Leerink Global Healthcare ConferenceYahoo Finance·Mar 3, 2026
- Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer ConferenceMarketbeat·Feb 28, 2026
- Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech SummitMarketbeat·Feb 14, 2026
- Lexeo Therapeutics to Participate in Upcoming Investor Conferences in FebruaryYahoo Finance·Feb 5, 2026
- H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 ProgramYahoo Finance·Feb 2, 2026
- Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA TherapeuticsYahoo Finance·Jan 27, 2026
- Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic CardiomyopathyYahoo Finance·Jan 12, 2026
- Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing dealBiopharmadive·Jan 9, 2026
- Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene TherapyYahoo Finance·Jan 8, 2026
- Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy PipelineYahoo Finance·Dec 27, 2025
- Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy’ StocksYahoo Finance·Dec 26, 2025
- Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Dec 22, 2025
- Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsightYahoo Finance·Dec 15, 2025
- Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) ForumYahoo Finance·Dec 4, 2025
- Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational HighlightsYahoo Finance·Nov 5, 2025
- Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside PotentialYahoo Finance·Nov 3, 2025
- Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity RaiseYahoo Finance·Oct 26, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$5.96
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$489M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume617K
Avg Volume (10D)—
Shares Outstanding78.5M
About Lexeo Therapeutics Inc
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—